tetano
Editor, Senior Moderator
Heliyon
. 2023 Sep 21;9(10):e20284.
doi: 10.1016/j.heliyon.2023.e20284. eCollection 2023 Oct. Metformin reduces the risk of developing influenza A virus related cardiovascular disease
Han Sol Lee[SUP] 1 [/SUP], Ji Yun Noh[SUP] 2 [/SUP], Joon Young Song[SUP] 2 [/SUP], Hee Jin Cheong[SUP] 1 2 [/SUP], Woo Joo Kim[SUP] 1 2 [/SUP]
Affiliations
This study investigated the drug repositioning potential of metformin for cardiovascular risk due to influenza A virus infection. Statistical analysis was performed to analyze factors related to the risk of death after IAV infection in diabetic patients. Through in vitro and in vivo experiments, the effect of metformin on influenza A virus infection in non-diabetic conditions was analyzed. In logistic regression analysis, influenza vaccination (OR = 0.378, p-value = 0.007, 0.186 < 95% C·I < 0.768) and metformin treatment (OR = 0.380, p-value = 0.016, 0.173 < 95% C·I < 0.835) were associated with a decreased influenza-related mortality in diabetic patients. In vitro and in vivo studies showed that viral replication and influenza A virus-induced cytokine expression were inhibited by metformin. In particular, MCP-1 and IP-10, cytokines related to cell infiltration and cardiovascular disease development, were significantly reduced by metformin under influenza A virus infection condition. As a result, the acute exacerbation of atherosclerosis caused by influenza A virus in mouse aorta was inhibited by metformin. In addition, we found that regulation of AKT/MAPK signaling plays an important role in the mechanism of metformin. In conclusion, we demonstrated the potential and mechanism of metformin as a treatment for acute exacerbation of atherosclerosis caused by influenza A virus infection.
Keywords: Cardiovascular diseases; IP-10; Influenza A virus; MCP-1; Metformin.
. 2023 Sep 21;9(10):e20284.
doi: 10.1016/j.heliyon.2023.e20284. eCollection 2023 Oct. Metformin reduces the risk of developing influenza A virus related cardiovascular disease
Han Sol Lee[SUP] 1 [/SUP], Ji Yun Noh[SUP] 2 [/SUP], Joon Young Song[SUP] 2 [/SUP], Hee Jin Cheong[SUP] 1 2 [/SUP], Woo Joo Kim[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37810823
- PMCID: PMC10556598
- DOI: 10.1016/j.heliyon.2023.e20284
This study investigated the drug repositioning potential of metformin for cardiovascular risk due to influenza A virus infection. Statistical analysis was performed to analyze factors related to the risk of death after IAV infection in diabetic patients. Through in vitro and in vivo experiments, the effect of metformin on influenza A virus infection in non-diabetic conditions was analyzed. In logistic regression analysis, influenza vaccination (OR = 0.378, p-value = 0.007, 0.186 < 95% C·I < 0.768) and metformin treatment (OR = 0.380, p-value = 0.016, 0.173 < 95% C·I < 0.835) were associated with a decreased influenza-related mortality in diabetic patients. In vitro and in vivo studies showed that viral replication and influenza A virus-induced cytokine expression were inhibited by metformin. In particular, MCP-1 and IP-10, cytokines related to cell infiltration and cardiovascular disease development, were significantly reduced by metformin under influenza A virus infection condition. As a result, the acute exacerbation of atherosclerosis caused by influenza A virus in mouse aorta was inhibited by metformin. In addition, we found that regulation of AKT/MAPK signaling plays an important role in the mechanism of metformin. In conclusion, we demonstrated the potential and mechanism of metformin as a treatment for acute exacerbation of atherosclerosis caused by influenza A virus infection.
Keywords: Cardiovascular diseases; IP-10; Influenza A virus; MCP-1; Metformin.